<DOC>
	<DOCNO>NCT03090659</DOCNO>
	<brief_summary>This single arm , open-label , multi-center , phase 1/2 study , determine safety efficacy LCAR-B38M CAR-T cell treat patient diagnose refractory/relapsed multiple myeloma ( r/r MM ) .</brief_summary>
	<brief_title>LCAR-B38M-02 Cells Treating Relapsed/Refractory ( R/R ) Multiple Myeloma</brief_title>
	<detailed_description>Multiple myeloma ( MM ) usually incurable malignancy plasma cell . Current therapy multiple myeloma often cause remission , nearly patient eventually relapse die , clear unmet clinical need . As early mid-2014 , investigator start develop series proprietary CAR-T product target B cell maturation antigen ( BCMA ) , cell surface molecule investigator believe desirable target antigen multiple myeloma . All pre-clinical data CMC data LCAR-B38M CAR-T cell technology establish mid-2015 phase I proof-of-concept clinical trial plan since .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Patients must confirm prior diagnosis active multiple myeloma define updated IMWG criterion . Patients refractory multiple myeloma . Clear BCMA expression must detect malignant plasma cell either bone marrow plasmacytoma flow cytometry immunohistochemistry . Refractory diseaseï¼š1 ) At least 3 prior regimen , must least contained bortezomi . 2 ) circumstance identify clinical doctor . Relapse criterion NCCN clinical practice guideline Oncology : Multiple Myeloma ( 2016.V2 ) Women childbearing potential pregnant breastfeeding . Have active uncontrolled infection : hepatitis B , hepatitis C , HIV , fatal viral bacterial infection . Systemic corticosteroid steroid therapy great 5 mg/day prednisone equivalent dose another corticosteroid allow within 2 week prior either required leukapheresis initiation condition chemotherapy regimen . Patients uncontrolled intercurrent illness serious uncontrolled medical disorder . Patients CNS metastasis symptomatic CNS involvement ( include cranial neuropathy mass lesion spinal cord compression ) . History allogeneic stem cell transplantation . Have active acute chronic graftversushostdisease ( GVHD ) , require immunosuppressant medication GVHD , within 6 month enrollment . Patients active autoimmune skin disease psoriasis active autoimmune disease rheumatoid arthritis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>multiple myeloma</keyword>
	<keyword>BCMA</keyword>
	<keyword>CAR-T</keyword>
</DOC>